Wiedermann Ursula, Garner-Spitzer Erika, Wagner Angelika
a Institute of Specific Prophylaxis and Tropical Medicine; Medical University Vienna ; Vienna , Austria.
Hum Vaccin Immunother. 2016;12(1):239-43. doi: 10.1080/21645515.2015.1093263.
There are 2 major factors responsible for vaccine failures, the first is vaccine-related such as failures in vaccine attenuation, vaccination regimes or administration. The other is host-related, of which host genetics, immune status, age, health or nutritional status can be associated with primary or secondary vaccine failures. The first describes the inability to respond to primary vaccination, the latter is characterized by a loss of protection after initial effectiveness. Our studies concentrate on the evaluation of immunological characteristics responsible for primary vaccine failures in different (risk) populations for which the underlying mechanisms are currently unknown. Here we summarise current knowledge and findings from our studies. About 2-10% of healthy individuals fail to mount antibody levels to routine vaccines. Comparing the immune responses to different vaccines in non-responder and high-responder vaccinees revealed that hypo-responsiveness is antigen/vaccine-specific at the humoral but not at the cellular level. We found that T-regulatory as well as B-regulatory cells and the production of IL-10 are involved in non/hypo-responsiveness. Non-responsiveness increases with age and in particular vaccination to a novel vaccine in persons > 65 years is associated with a high low/non-responder rate, indicating that vaccine schedules and doses (at least for primary vaccination) should be adapted according to age. In light of the growing number of allergic but also obese people, our current studies concentrate on these risk groups to reveal whether different vaccination approaches are necessary for optimal protection compared to healthy individuals. These studies are in line with the significant paradigm shift taking place in many fields of medical research and care, and will extend the concept of personalised medicine into the field of vaccinology.
疫苗失效主要有两大因素,第一个与疫苗相关,比如疫苗减毒、接种方案或接种操作失败。另一个与宿主相关,其中宿主的遗传学、免疫状态、年龄、健康状况或营养状况可能与原发性或继发性疫苗失效有关。前者描述的是对初次接种无反应的情况,后者的特征是在初始有效后失去保护作用。我们的研究集中于评估不同(风险)人群中导致原发性疫苗失效的免疫特征,而目前这些人群中潜在的机制尚不清楚。在此,我们总结当前的知识以及我们研究中的发现。约2% - 10%的健康个体对常规疫苗无法产生抗体水平。比较无反应者和高反应者对不同疫苗的免疫反应发现,低反应性在体液水平上是抗原/疫苗特异性的,但在细胞水平上并非如此。我们发现调节性T细胞以及调节性B细胞和白细胞介素 - 10的产生与无反应/低反应性有关。无反应性随年龄增长而增加,特别是65岁以上人群接种新型疫苗时,低反应/无反应率较高,这表明疫苗接种方案和剂量(至少对于初次接种)应根据年龄进行调整。鉴于过敏人群和肥胖人群数量不断增加,我们目前的研究集中在这些风险群体,以揭示与健康个体相比,是否需要不同的接种方法来实现最佳保护。这些研究与医学研究和护理的许多领域正在发生的重大范式转变相一致,并将把个性化医疗的概念扩展到疫苗学领域。